Genprex (GNPX) Osake Kurssi

Genprex, Inc. is a clinical-stage gene therapy company focused on developing potentially life-changing technologies for patients with cancer and diabetes. The company is headquartered in Austin, Texas and currently employs 12 full-time employees. The company went IPO on 2018-03-29. The firm is focused on developing cancer-based upon its novel technology platform, including its initial product candidate, Oncoprex, immunogene therapy, or Oncoprex. Oncoprex consists of a tumor suppressor gene inserted into a patient’s cells that has immunomodulatory effects and is thereby considered an immunogene therapy. The gene is one of a series of genes whose therapeutic use is covered by a license from The University of Texas MD Anderson Cancer Center (MD Anderson). The company is also developing a pre-clinical gene therapy that is covered by a license from the University of Pittsburgh of the Commonwealth System of Higher Education that has the potential to cure type 1 and type 2 diabetes. The company is developing its product candidate to be administered with targeted therapies and with immunotherapies for non-small cell lung cancer (NSCLC).